En vivo

FierceBiotechRegeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy FierceBiotechVincentage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators PharmaVoiceRace intensifies to lead next wave of obesity drugs as trial results loom FierceBiotechBoston Scientific funnels $1.5B into MiRus, with option to buy TAVR system LabiotechNew antidepressants: Tackling treatment resistant depression Thermo FisherThermo Fisher Scientific Expands PPD Laboratory Services Network With New Bioanalytical Facility In Sweden - BioPharma APAC Thermo FisherThermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden - The Joplin Globe FierceBiotechWhere the Promise of NAMs Meets Practice FierceBiotechOhio Discovery Corridor is Attracting the World’s Best in Pediatric Research. Here’s Why Thermo FisherThermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden - Business Wire BioPharma DiveRegeneron immunotherapy combo comes up short in melanoma trial Endpoints NewsRegeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3

Endpoints News 18 may 2026

FDA approves AstraZeneca’s baxdrostat for certain patients with hypertension

One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday. The b...

One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday. The blood ...